CRISPR Therapeutics and Casebia Therapeutics Announce Exclusive Development and Option Agreement with … – Yahoo Finance
Petro Global News 24 |
CRISPR Therapeutics and Casebia Therapeutics Announce Exclusive Development and Option Agreement with …
Yahoo Finance CRISPR Therapeutics and Casebia will have an option to exclusively license AAV vectors with desired properties for use in their in vivo gene-editing programs. StrideBio will receive development funding, milestones and royalties on licensed vectors, and … Crispr Therapeutics AG (CRSP) Given Consensus Recommendation of "Strong Buy" by Analysts The Brokerages Set $25.83 Target Price for Crispr Therapeutics AG (CRSP) Crispr Therapeutics AG (CRSP) Coverage Initiated by Analysts at Chardan Capital |
